中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
209-211
,共3页
多西他赛%曲妥珠单抗%转移性乳腺癌%HER-2强表达%护理
多西他賽%麯妥珠單抗%轉移性乳腺癌%HER-2彊錶達%護理
다서타새%곡타주단항%전이성유선암%HER-2강표체%호리
docetaxel%herceptin%metastatic breast cancer HER-2 strong expression%nursing
目的 探讨转移性乳腺癌HER-2强表达患者采用曲妥珠单抗及多西他赛治疗联合护理的临床效果.方法 将2011年3月至2014年5月收治的150例转移性乳腺癌HER-2强表达患者按随机数字表法分为研究组和对照组,各75例.对照组患者仅使用曲妥珠单抗及多西他赛药物治疗,研究组患者在对照组基础上联合护理干预措施.结果 研究组患者接受3个月的治疗后发热、皮疹、骨髓抑制、胃肠道不适等不良反应发生率均低于对照组(χ2=7. 2921,P=0. 006 9<0. 05);两组患者治疗3个月后的卡氏生活质量评分( KPS )和生活质量评定量表评分( QOL )显著高于治疗前( P<0. 05),且研究组评分显著高于对照组( P<0. 05);治疗3个月后,研究组患者的病情稳定、疾病进展发生率分别为6. 67%和2. 66%,均低于对照组患者的2. 66%和18. 67%(χ2=10. 074 6,P=0. 001 5<0. 05).结论 转移性乳腺癌HER-2强表达患者在采用曲妥珠单抗及多西他赛治疗基础上联合护理干预措施疗效更显著,可降低不良反应发生率,改善生活质量,促进机体康复,值得临床推广.
目的 探討轉移性乳腺癌HER-2彊錶達患者採用麯妥珠單抗及多西他賽治療聯閤護理的臨床效果.方法 將2011年3月至2014年5月收治的150例轉移性乳腺癌HER-2彊錶達患者按隨機數字錶法分為研究組和對照組,各75例.對照組患者僅使用麯妥珠單抗及多西他賽藥物治療,研究組患者在對照組基礎上聯閤護理榦預措施.結果 研究組患者接受3箇月的治療後髮熱、皮疹、骨髓抑製、胃腸道不適等不良反應髮生率均低于對照組(χ2=7. 2921,P=0. 006 9<0. 05);兩組患者治療3箇月後的卡氏生活質量評分( KPS )和生活質量評定量錶評分( QOL )顯著高于治療前( P<0. 05),且研究組評分顯著高于對照組( P<0. 05);治療3箇月後,研究組患者的病情穩定、疾病進展髮生率分彆為6. 67%和2. 66%,均低于對照組患者的2. 66%和18. 67%(χ2=10. 074 6,P=0. 001 5<0. 05).結論 轉移性乳腺癌HER-2彊錶達患者在採用麯妥珠單抗及多西他賽治療基礎上聯閤護理榦預措施療效更顯著,可降低不良反應髮生率,改善生活質量,促進機體康複,值得臨床推廣.
목적 탐토전이성유선암HER-2강표체환자채용곡타주단항급다서타새치료연합호리적림상효과.방법 장2011년3월지2014년5월수치적150례전이성유선암HER-2강표체환자안수궤수자표법분위연구조화대조조,각75례.대조조환자부사용곡타주단항급다서타새약물치료,연구조환자재대조조기출상연합호리간예조시.결과 연구조환자접수3개월적치료후발열、피진、골수억제、위장도불괄등불량반응발생솔균저우대조조(χ2=7. 2921,P=0. 006 9<0. 05);량조환자치료3개월후적잡씨생활질량평분( KPS )화생활질량평정량표평분( QOL )현저고우치료전( P<0. 05),차연구조평분현저고우대조조( P<0. 05);치료3개월후,연구조환자적병정은정、질병진전발생솔분별위6. 67%화2. 66%,균저우대조조환자적2. 66%화18. 67%(χ2=10. 074 6,P=0. 001 5<0. 05).결론 전이성유선암HER-2강표체환자재채용곡타주단항급다서타새치료기출상연합호리간예조시료효경현저,가강저불량반응발생솔,개선생활질량,촉진궤체강복,치득림상추엄.
Objective To explore the clinical efficacy of docetaxel and herceptin combined with nursing intervention in treating metastat-ic breast cancer HER-2 strong expression. Methods 150 patients with metastatic breast cancer HER-2 strong expression from March 2011 to May 2014 were randomly divided into study group and control group, 75 casesin each group. The control group simply received docetaxel and herceptin therapy, the study group added nursing interventions. Results 3 months after treatment, fever, rash, bone marrow suppression, gastrointestinal discomfort and other adverse reactions in the study group were lower than those in the control group (χ2=7. 292 1, P=0. 006 9 < 0. 05 ); the KPS and QOL scores of the two groups were significantly higher than before treatment, and the study group was significantly higher than the control group( P < 0. 05);the rates of SD and PD cases in the study group were 6. 67%, 2. 66%, which were lower than 2. 66%, 18. 67% of the control group (χ2=10. 074 6, P=0. 001 5 < 0. 05 ) . Conclusion Docetaxel and herceptin combined with nursing interventions in treating patients with metastatic breast cancer HER-2 strong expression can achieve more significant clinical effect, reduce the incidence of adverse reactions, improve the quality of life of patients, promote body recovery, and is worthy of clinical application.
